Enfoque diagnóstico y terapéutico de dispepsia y dispepsia funcional: ¿qué hay nuevo en el 2019? / Diagnostic and therapeutic approach to dyspepsia and functional dyspepsia: what's new in 2019?

La dispepsia abarca un conjunto de síntomas que se originan en la región gastroduodenal. Se caracteriza por dolor o ardor epigástrico, saciedad precoz y llenura pos-prandial. Según la relación de los síntomas con las comidas se divide en síndrome de dolor epigástrico y síndrome de malestar pos-prandial. Sin embargo, en la práctica clínica, frecuentemente se sobreponen. En los últimos años se ha cambiado el paradigma de las alteraciones fisiológicas gástricas y han aumentado las evidencias que apoya a la eosinofilia duodenal, como una alteración primaria que altera la fisiología gástrica y puede inducir la sintomatología. Así mismo, cada día hay mayor interés en la alteración de la microbiota. El tratamiento se basa en la supresión de ácido, procinéticos, neuromoduladores, psicoterapia, terapias alternativas y complementarias. Ningún tratamiento es universalmente eficaz en todos los pacientes.

Dyspepsia encompasses a set of symptoms that originate in the gastroduodenal region. It is characterized by pain or epigastric burning, early satiety and post-prandial fullness. According to the relationship of symptoms with meals, it is divided into epigastric pain syndrome and postprandial distress syndrome. However, in clinical practice, they frequently overlap. In recent years the paradigm of gastric physiological alterations has been changed and evidence supporting duodenal eosinophilia has increased, as a primary alteration that alters gastric physiology and can induce symptomatology. Every day there is more interest in the alteration of the microbiota. The treatment is based on the suppression of acid, neuromodulators, prokinetics, psychotherapy, alternative and complementary therapies. No treatment is effective in all patients.

El escrutinio diagnóstico limitado puede disminuir el impacto económico directo del síndrome de intestino irritable (SII) / Limited diagnostic testing can decrease the direct economic impact of irritable bowel syndrome

Background: The economic impact of irritable bowel syndrome (IBS) in México in terms of excessive diagnostic testing can be considerably reduced if the recommendations of the Latín American Consensus (LATAM) for IBS are followed. Aim: To estímate the economic impact of IBS in terms of excessive diagnostic testing. Material and Methods: Based on a previously published study the costs of diagnostic testing for IBS were compared to the theoretical costs according to the recommendations of the consensus. These costs were compared to estímate the economic impact of excessive diagnostic testing. A cost-minimization analysis was also done. Results: For the lowest socioeconomic level in academic medicine, the excessive diagnostic testing had an approximate cost of US$21.38, compared to US$1.72 if the LATAM Consensus recommendations would have been followed, representing a saving of 92.0 percent. The cost for the highest socioeconomic level in academic medicine was US$1080.36 versus US$103.60 (a saving of 90.4 percent) and for prívate medicine, the costs were US$3121.60 versus US$159.90 (a saving of 94.9 percent) if the recommendations would have been followed. Conclusions: Limited diagnostic testing recommended by the LATAM Consensus for IBS can significantly decrease the economic impact of this disease in México.

Evaluación de la ecografía en la medición del volumen tiroideo

Llevamos a cabo un estudio piloto para determinar la concordancia de la ecografía para medir el volumen de la tiroides, como parte de un protócolo para determinar la respuesta del bocio simple a la terapia supresiva. Examinamos diez sujetos con bocio y diez sujeto sanos, repitiendo el procedimiento una semana después y comparando el volumen de la tiroides, y que la variabilidad en la concordancia está dada por los sujeto examinados, lo que puede obedecer a la presencia de mayor o menor tejido adiposo o muscular en el cuello.